National Hospital Organization Shikoku Cancer Center Hospital

Matsuyama-shi, Japan

National Hospital Organization Shikoku Cancer Center Hospital

Matsuyama-shi, Japan
SEARCH FILTERS
Time filter
Source Type

PubMed | Red Cross, National Hospital Organization Shikoku Cancer Center Hospital, Kumamoto University, Kyushu University and 6 more.
Type: Clinical Trial, Phase II | Journal: Clinical lung cancer | Year: 2016

Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction therapy will receive cisplatin and docetaxel (40 mg/m(2)) on days 1, 8, 29, and 36, and concurrent 3-dimensional conformal thoracic radiotherapy with a single daily fraction of 2 Gy, for 5 consecutive days each week to provide a total dose of 60 Gy. The primary end point is overall survival at 24 months. A target sample size of 21 evaluable patients is considered sufficient to validate an expected rate of 85%, and 60% would be the lower limit of interest, with 80% power and a 1-sided of 5%. Secondary end points include toxicity, response rate, and overall survival. This study will clarify whether tyrosine kinase inhibitors targeted to EGFR can produce a maximal effect in selected NSCLC patients with the relevant driver mutation, even in the locally advanced setting.

Loading National Hospital Organization Shikoku Cancer Center Hospital collaborators
Loading National Hospital Organization Shikoku Cancer Center Hospital collaborators